BioSpace News Archive

Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone.

Hybrigenics, a leading French publicly listed bioscience firm, has today announced its re-brand to ‘ATON’ as it signifies the culmination of a transformative shift in its vision and strategy that began two years ago.

Partillion Bioscience Corporation announced the closing of a $5 million seed financing round, expansion of its board of directors, and a multiyear agreement with Alloy Therapeutics, Inc. as a Preferred Partner providing antibody discovery services using Partillion’s Nanovial technology.

In the exciting, growing field of Spatial Biology, the Orion platform from RareCyte has emerged as the platform of choice across biomarker discovery, translational and clinical research.

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year.

Varian, a Siemens Healthineers company, announced today that it has acquired Aspekt Solutions, a leading provider of medical physics, dosimetry, and strategy consultation services.

Cincinnati Children’s, the top ranked pediatric hospital and top ranked cancer program in the country by U.S. News & World Report, continues to break new ground with the launch of the first of its kind Advanced Leukemia Therapies and Research Center.

Strata Oncology, Inc. (“Strata”), a next-generation precision oncology company enabling smarter cancer treatment, today announced the appointment of Goz Alhir as Senior Vice President, Commercialization.

Immunis, Inc. is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland.

CEL-SCI Corporation reported it has filed a request for Scientific Advice regarding Multikine* immunotherapy for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck with the European Medicines Agency’s Scientific Advice Working Group.